Split Fed Circuit refuses Teva 'skinny label' ruling review

A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva asks Fed Circ for ‘skinny label’ redo

12 October 2021 Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Generics

Teva asks Fed Circ for ‘skinny label’ redo

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Generics

Teva asks Fed Circ for ‘skinny label’ redo

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.